TLX
NEUTRALAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Trades at a significant premium to book value; valuation is driven by future expectations rather than current assets.
- Forward P/E is reasonable for high-growth biotech
- High Price/Book (8.75)
- No Graham Number available due to lack of earnings
Growth metrics are the primary driver of the bullish analyst outlook.
- Exceptional revenue growth (49.3%)
- High analyst target price ($21.64)
- Dependence on scaling to reach profitability
Historical price performance has been poor, reflecting a long-term bearish trend.
- Recent 1-month recovery
- Negative 1Y, 3Y, and 5Y returns
- Consistent downward trend over long horizons
Deterministic health scores indicate severe financial instability.
- Current ratio above 1.0
- Piotroski F-Score of 1/9 is a major red flag
- Debt/Equity of 1.12 is high for a non-profitable entity
Typical for biotech; all capital is reinvested or used for operations.
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for TLX and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
TLX
Telix Pharmaceuticals Limited
Primary
|
-29.2% | -29.2% | -33.8% | -0.6% | +22.6% | -4.5% |
|
ADMA
ADMA Biologics, Inc.
Peer
|
+604.6% | +370.5% | -15.4% | -6.0% | -6.9% | -1.6% |
|
KNSA
Kiniksa Pharmaceuticals International, plc
Peer
|
+191.5% | +337.6% | +152.4% | +24.2% | +1.7% | -3.6% |
|
TVTX
Travere Therapeutics, Inc.
Peer
|
+55.7% | +89.8% | +166.6% | +44.5% | +50.1% | +31.2% |
|
AMRX
Amneal Pharmaceuticals, Inc.
Peer
|
+69.5% | +727.3% | +34.6% | +18.3% | -19.5% | -10.7% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
TLX
Telix Pharmaceuticals Limited
|
NEUTRAL | $3.64B | - | -1.9% | -0.9% | $10.73 | |
|
ADMA
ADMA Biologics, Inc.
|
BEARISH | $3.61B | 25.25 | 35.6% | 28.8% | $15.15 | Compare |
|
KNSA
Kiniksa Pharmaceuticals...
|
NEUTRAL | $3.6B | 62.77 | 11.7% | 8.7% | $47.08 | Compare |
|
TVTX
Travere Therapeutics, Inc.
|
BULLISH | $3.72B | - | -57.8% | -5.2% | $40.29 | Compare |
|
AMRX
Amneal Pharmaceuticals, Inc.
|
BEARISH | $3.72B | 53.77 | -% | 2.4% | $11.83 | Compare |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning TLX from our newsroom.